Protalix BioTherapeutics Reports 2025 Financial Results, Advances Fabry Disease and Gout Programs, and Updates 2026 Guidance.

Protalix BioTherapeutics reported 2025 financial results and outlined developments, including a new European approval for Fabry disease therapy Elfabrio and updated 2026 guidance. The EC approved a 2 mg/kg every-four-weeks dosing regimen for Elfabrio, reducing treatment burden while maintaining efficacy. The company expects total revenue in 2026 to range between $78 million and $83 million, including a $25 million milestone payment from partner Chiesi.